WO2004048496A1 - 酸化安定性が向上された二重結合を有する有機物を含有する組成物 - Google Patents
酸化安定性が向上された二重結合を有する有機物を含有する組成物 Download PDFInfo
- Publication number
- WO2004048496A1 WO2004048496A1 PCT/JP2003/014877 JP0314877W WO2004048496A1 WO 2004048496 A1 WO2004048496 A1 WO 2004048496A1 JP 0314877 W JP0314877 W JP 0314877W WO 2004048496 A1 WO2004048496 A1 WO 2004048496A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ascorbic acid
- sesame
- acid
- fatty acid
- composition according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
- A23D9/013—Other fatty acid esters, e.g. phosphatides
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
- C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
- C09K15/06—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing oxygen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
- C09K15/34—Anti-oxidant compositions; Compositions inhibiting chemical change containing plant or animal materials of unknown composition
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B5/00—Preserving by using additives, e.g. anti-oxidants
- C11B5/0021—Preserving by using additives, e.g. anti-oxidants containing oxygen
- C11B5/0028—Carboxylic acids; Their derivates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Definitions
- composition containing organic substance having double bond with improved oxidation stability containing organic substance having double bond with improved oxidation stability
- the present invention relates to a method for producing a compound containing an organic substance having a double bond with improved oxidation stability.
- composition More specifically, oxidation stability is obtained by adding an antioxidant component of sesame and ascorbic acid or a fatty acid ester of ascorbic acid as an antioxidant to an organic substance having a double bond which is easily oxidized such as a highly unsaturated fatty acid.
- a composition having improved properties.
- the polyunsaturated fatty acid is a fatty acid having three or more double bonds.
- fats and oils especially fats and oils containing polyunsaturated fatty acids, have been known to have physiological effects, and have been widely used as additives for foods and feeds, etc., from the health perspective.
- Eicosapentaenoic acid and docosahexaenoic acid are polyunsaturated fatty acids mainly contained in fish oil, and they have been found to have various effects such as prevention of hyperlipidemia, hypertension, and prevention of skin aging. It is used as a food material and pharmaceutical for health promotion.
- fats and oils containing polyunsaturated fatty acids have low oxidative stability, which limits not only the foods that can be added, but also odors caused by slight oxidation during the manufacturing process when added to foods.
- Nitrogen gas is applied to the cans of refined fish oil remaining after use. Consideration must also be given to the handling of fats and oils, such as the need to seal them after they have been sealed, and their use, such as the type of product, distribution temperature, and the amount added, has naturally been limited.
- docosahexaenoic acid and eicosapentaenoic acid play an important role in the development of the brain and retina of infants and the ability to learn and learn from memory.Since these fatty acids are contained in breast milk, they are used for childcare. Fish oil containing docosahexanoic acid and eicosapentaenoic acid is added to the prepared milk and is commercially available.
- arachidonic acid plays an important role in growth and is contained in breast milk. Therefore, attempts have been made to add arachidonic acid to infant formula. However, when these polyunsaturated fatty acids are incorporated into infant formula, care must be taken not to oxidize the polyunsaturated fatty acids. Even when it is transformed and becomes toxic. Eicosapentaenoic acid ethyl ester is marketed as a drug for oral administration in capsule form. Refined fish oils containing eicosapentaenoic acid and docosahexaenoic acid are also sold as capsules in health foods. Due to its oxidizing effect, its use other than in capsules is limited.
- Powdering is one of the modes of improving the oxidative stability of these fats and oils.
- the fats and oils are encapsulated in a mic mouth capsule and powdered, or the fats and oils are packaged and powdered with cyclodextrin.
- the method has been adopted.
- antioxidants have been used to improve the oxidative stability of fats and oils.
- the antioxidant properties are improved by combining a plurality of antioxidants or adding an antioxidant and a synergist such as phosphoric acid, cunic acid, and ascorbic acid.
- Sesame oil is relatively stable against oxidation, so sesame must contain antioxidant components Has been known for a long time, and is known to contain sesamol and various kinds of redanans (Japanese Patent Application Laid-Open No. 58-132076, Food Science, 225 (11) p. 40-48 (1996) and Ibid., 225 (11) p.32-36 (1996)).
- sesamol is an oil and fat-containing antioxidant approved as a food additive, it has been reported that it has no effect on fats and oils with extremely low oxidative stability such as fish oil.
- Hatsuyu Yushi Co., Ltd. DHA Advanced Refining Extraction Technology Development Project FY 1994-1996 Summary of Results (DHA Advanced Refining Extraction Technology Research Association) P74-79 (2002)), used for improving the oxidation stability of fish oil Not.
- ascorbic acid or ascorbic acid derivatives are food additives.
- Oils and fats that are recognized as antioxidants for foods containing oils and fats S, oils with very low oxidation stability such as fish oil alone have no effect, and even when combined with tocopherol, The effect is not enough.
- Japanese Patent Application Laid-Open No. 2002-142,733 discloses a lipophilic oxidation obtained by emulsifying gallic acid, a water-soluble antioxidant and an oil-soluble antioxidant in a water-in-oil type with a lipophilic emulsifier. Inhibitors are described.
- Vitamin C cunic acid, chlorogenic acid and its derivatives, sugar amino reactants, proanthocyanins, flavone derivatives, tea extract, bud seed extract and rutin as water-soluble antioxidants, and oil
- the soluble antioxidant include tocophere, ascorbic acid, noremitate, sesamol, and ⁇ -oryzanol.
- the effects of various antioxidants on the thermal decomposition of tocopherol in fats and oils have been compared.
- An object of the present invention is to provide an organic substance having a double bond, which has significantly improved oxidative stability, particularly a highly unsaturated fatty acid or an ester thereof.
- the present inventors have conducted various studies to improve the oxidative stability of fats and oils (fats and oils rich in highly unsaturated fatty acids, for example, marine animal oils such as fish oil). As a result, sesamol and ascorbic acid or ascorbic acid fatty acid were It has been found that the oxidation stability of fats and oils can be significantly improved by adding esters in combination.
- the inventors have found that the combination of ascorbic acid or fatty acid esters of ascorbic acid in sesame antioxidants other than sesamol significantly increases the antioxidant effect, and thus completed the present invention.
- the gist of the present invention is a composition described in the following (1) to (13).
- (1) A composition containing an organic substance having oxidative stability and a double bond, to which sesame antioxidant and ascorbic acid or fatty acid ester of ascorbic acid are added as antioxidants.
- composition according to (1) wherein the organic substance having a double bond is a polyunsaturated fatty acid, a salt thereof, or an ester thereof.
- the polyunsaturated fatty acid is a fatty acid containing at least one of eicosapentaenoic acid and docosahexaenoic acid.
- composition according to (3) or (4), wherein the ester of the polyunsaturated fatty acid is triglyceride or a lower alcohol ester of the polyunsaturated fatty acid containing the polyunsaturated fatty acid as a constituent.
- composition according to (3) or (4), wherein the ester of polyunsaturated fatty acid is contained as refined fish oil.
- Antioxidant components of sesame are detected by high performance liquid chromatography using an electrochemical detector. Elution times are 2.66, 3.40, 3.84, 4.57, 4.98, 5.82, 7.00, 8.67, 9.84, 11.24, 12.29, 12.49, 13.36, 14.04, 14.32, 14.7 4, 15.22, 15.60, 15.82, 16.34, 16.98, 18.10, 18.43, 34.91 Contains at least one or more components that show a peak at around 1 minute (1) or (6) Any composition.
- composition according to any one of (1) to (6), wherein the antioxidant component of sesame is an extract of sesame, sesame oil or sesame meal using a solvent, lipid, or an emulsifier alone or in a mixed solvent.
- the antioxidant components of sesame are sesamol, sesaminol, episesaminol, pinoresinore, epihinoresinole, silyngaresinole, samin, sesamolinol, 2,3-di (4, -hydroxy3 ' -Methoxybenzyl)-2-butene-At least one selected from 2,3-di (4'-hydroxy-3'-methoxybenzyl) -2-bute ⁇ -4-olide) (1)
- the composition according to any one of (1) to (6).
- Ascorbic acid or fatty acid esters of ascorbic acid (1) The composition according to any one of (1) to (10), to which an excess of a soluble fatty acid, a salt thereof, or an ester thereof is added in an excess amount.
- Oxidation stability of a composition containing a double bond having an active methylene having low oxidation stability or an organic substance having a terminal double bond, particularly a composition containing a polyunsaturated fatty acid can be remarkably improved.
- a polyunsaturated fatty acid-containing composition it is possible to easily add to pharmaceuticals, cosmetics, foods and the like, which have been restricted, and to increase the amount of the composition. Since both the sesame antioxidant component, ascorbic acid and ascorbic acid fatty acid ester used in the present invention have a long eating experience, they can provide a safe antioxidant even when used in food.
- FIG. 1 is a view showing the amount of oxygen absorbed by the fat and oil of Example 1.
- FIG. 2 is a diagram showing the amount of oxygen absorbed by the fats and oils of Example 2.
- FIG. 3 is a diagram showing the amount of oxygen absorbed by the fats and oils of Example 3.
- FIG. 4 is a diagram showing the amount of oxygen absorbed by the fat and oil of Example 4.
- FIG. 5 is a diagram showing the amount of oxygen absorbed by the fat and oil of Example 5.
- FIG. 6 is a chart of a high-speed liquid mouth chromatograph using an electrochemical detector of sesame meal extract 1 of Example 6.
- FIG. 7 is a graph showing changes in the amount of oxygen absorbed by the sample of Example 6.
- FIG. 8 is a graph showing the transition of the malondialdehyde concentration of the sample of Example 7.
- FIG. 9 is a graph showing changes in the alkenal concentration of the sample of Example 7.
- FIG. 10 is a graph showing changes in the amount of oxygen absorbed and the remaining amount of the antioxidant in the sample of Example 8 (sesamol 0.5 ° /.).
- FIG. 11 is a graph showing changes in the amount of oxygen absorbed and the amount of the remaining antioxidant in the sample of Example 8 (sesamol 1.0%).
- FIG. 12 is a graph showing changes in the amount of oxygen absorbed and the remaining amount of antioxidant in a sample when ascorbic acid palmitate was added four days after Example 8.
- FIG. 13 is a diagram showing the transition of the PV of the sample of the ninth embodiment.
- FIG. 14 is a drawing showing a comparison of the antioxidant effects of BHT and the antioxidant formulation of the present invention.
- the organic substance having a double bond targeted in the present invention is an organic substance which is easily oxidized even when stored at room temperature and is easily oxidized.
- it is a double bond having active methylene or an organic substance having a terminal double bond, and examples thereof include unsaturated lipids and polymer raw materials (monomers).
- unsaturated lipids particularly highly unsaturated fatty acids having four or more double bonds are very easily oxidized, and conventional antioxidants cannot sufficiently suppress oxidation.
- the polyunsaturated fatty acids or esters thereof targeted in the present invention include polyunsaturated fatty acids, esters of lower alkyl of polyunsaturated fatty acids, and triglycerides containing polyunsaturated fatty acids as constituents.
- polyunsaturated fatty acids mean fatty acids having a degree of unsaturation of 3 or more. In particular, the effect is remarkable for fatty acids having an unsaturation degree of 4 or more.
- Examples of the highly unsaturated fatty acids having an unsaturation degree of 3 or more include ⁇ -linolenic acid, arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid.
- the highly unsaturated fatty acids of the present invention also include ester derivatives such as methyl esters, ethyl esters, triglycerides, diglycerides, and monoglycerides of the fatty acids.
- Eicosapentaenoic acid is a generic term for unsaturated fatty acids having 20 carbon atoms and 5 double bonds, but as a natural product, the position of the double bond is 5, 8, 11, 11, 14 or 17 And refers to all cis-type linear pentaunsaturated ⁇ _3 fatty acids.
- Docosahexaenoic acid is a straight-chain hexanoic acid having 22 carbon atoms having a cis double bond at the 4, 7, 10, 13, 16 and 19 positions.
- EPA and DHA derived from these natural products are contained as such in natural fats and oils, particularly marine fats and oils such as tuna, skipjack, mackerel, sardine, and cod, or as derivatives thereof such as glyceride.
- the present invention relates to a raw material for fats and oils containing a polyunsaturated fatty acid having a degree of unsaturation of 3 or more. Anything can be used.
- Raw materials containing polyunsaturated fatty acids include sardines, mackerel, saury, tuna, bonito, etc., marine fish, microorganism-derived lipids, krill, shrimp and other crustaceans, fish oil, animal and vegetable oils, genetically modified vegetable oils, etc. It can be a raw material.
- the fats and oils containing the polyunsaturated fatty acids having the degree of unsaturation of 3 or more can be concentrated by wintering treatment, enzymatic treatment and the like.
- the fats and oils containing a polyunsaturated fatty acid having a degree of unsaturation of 3 or more are converted into fatty acid or ester with alcohol, and subjected to distillation treatment, urea addition treatment, column treatment, enzyme treatment, supercritical carbon dioxide treatment, etc. Highly unsaturated fatty acids can be concentrated.
- the antioxidant of the present invention does not reduce the already oxidized one, it is necessary to use an organic substance having a double bond from which the oxide has been removed before adding the antioxidant.
- oxides must be removed by degumming, deacidifying, decolorizing, and deodorizing, etc.
- Omeq / kg or less, AV is 1.0 or less, and it is preferably organoleptically odorless.
- the antioxidant of the present invention does not have a function of reducing oxidized products, it is desirable to use an organic substance to be added having a high degree of purification from which oxides have been removed as much as possible. Since the odor due to oxidation is generated by slight oxidation, it is necessary to use a purified one before adding antioxidants. In the case of refined fish oil, it is preferable to use a purified product that has a PV of 3.0 Omeq / kg or less, an AV of 1.0 or less, and is functionally odorless.
- the unsaturated fatty acid which is one of the objects contained in the composition of the present invention
- the rancidity of the fats and oils to be separated can be due to hydrolysis or oxidation.
- the inferior flavor associated with the oxidation is due to the decomposition products of hydroperoxide generated by the oxidation, such as the oxidation of soybean oil to propionaldehyde, 2-pentenal, capronaldehyde, acetate crotonaldehyde, etc.
- hydroperoxide generated by the oxidation such as the oxidation of soybean oil to propionaldehyde, 2-pentenal, capronaldehyde, acetate crotonaldehyde, etc.
- Fish oils have an unpleasant odor due to the oxidation of the highly unsaturated fatty acids in them, which give off a distinctive smell.
- Refined oils containing unsaturated fatty acids such as fish oil, soybean oil, linseed oil, and rapeseed oil, can produce unpleasant odors and color deterioration even at the very beginning of oxidation. This phenomenon is called modori.
- the color of the bleached vegetable refined oil is due to chroman-1,5,6-quinone, an oxidation product of vitamin E.
- the present invention suppresses the oxidation of unsaturated fatty acids, and particularly remarkable effects are observed in animal oils having low oxidation stability.
- Other examples of the organic substance having a double bond which is the object of the present invention include tapes, cataplasms, wound dressings and the like containing pharmaceuticals, in which a polymer having a double bond is used as a base component. Is done.
- the present invention can be used for rubber-based polymers such as butadiene rubber, styrene-butadiene rubber,NICa rubber, chloroprene rubber, acryl rubber, natural rubber, isoprene rubber, and styrene-isoprene-styrene block copolymer.
- rubber-based polymers such as butadiene rubber, styrene-butadiene rubber,NICadiene rubber, NIC, acryl rubber, natural rubber, isoprene rubber, and styrene-isoprene-styrene block copolymer.
- antioxidants usually used.
- various phenol-type antioxidants contained in sesame can be used.
- the antioxidant component of sesame used in the present invention may be highly purified from sesame, or may contain a sesame-derived substance, sesame lignans, tocopherols, etc. together with lightly purified antioxidant components such as sesamol. I don't care. Alternatively, it may be a chemically synthesized product.
- sesame oil can be used as is, as long as there is no problem with the odor unique to sesame oil.
- the antioxidant component can be extracted from sesame seed, sesame oil, or sesame defatted lees after squeezing sesame oil. It can also be obtained from scum, a component distilled when sesame oil is deodorized. Roasted sesame is preferred because of the increase in antioxidant components, but sesame that has not been roasted can also be used because it contains certain antioxidant components. When extracting from sesame seeds, it is preferable to compress the neutral lipid, which is the main component, or remove it with a non-polar solvent such as hexane. Sesame oil can be used as it is, but its use is limited because the absolute amount of neutral lipids is large and the proportion of antioxidant components is low.
- sesame extract of the present invention any solvent, lipid, or milk can be used as long as it can extract an antioxidant component as shown by the HPLS peak in FIG.
- Those extracted with an agent can also be used.
- sesame, sesame oil or sesame meal is converted from nitrous oxide, acetone, ethanol, ethyl methyl ketone, glycerin, ethyl acetate, methyl acetate, getyl ether, cyclohexane, dichloromethane, 1,1,1,2- Organic solvents such as tetrafurenoleo ethane, 1,1,2-trichloroethene, carbon dioxide, 1-butanol, 2-butanol, butane, 1-propanol, 2-propanol, propane, propylene glycol, hexane, and methanol ⁇ It can be obtained by extraction with an emulsifier such as a lipid such as triglyceride, diglyceride, monod
- the antioxidant component can be concentrated by dissolving it again in an organic solvent or the like and removing water-soluble components by partitioning with water, or removing insoluble components by filtration. .
- the amount of the antioxidant added can be reduced depending on the storage conditions and the storage period.
- the added amount of sesame antioxidant is effective if it is added to polyunsaturated fatty acids in an amount of 0.5% or more. It is preferable to add 1% or more.
- the solubility of ascorbic acid fatty acid ester in polyunsaturated fatty acids is limited to about 0.1%, but if added excessively, the sustainability of the antioxidant effect increases, so it should be increased as appropriate according to the purpose. Can be.
- Ascorbic acid or fatty acid ester of ascorbic acid used in the present invention includes asconoleic acid, ascorbic acid panolemitic acid ester, and asconoleic acid.
- Ascorbic acid fatty acid esters such as formic acid stearate can be used.
- ascorbic acid salts and the like can be used, but those having high solubility in lipids are preferable.
- antioxidants of the present invention ascorbic acid or fatty acid ester of ascorbic acid can be used in excess of the soluble amount to further enhance the durability of the antioxidant action.
- an antioxidant When adding an antioxidant to fats and oils, it is considered meaningless if it is not dissolved.Therefore, it is not added above the saturation concentration, but as shown in Examples 11 to 12,
- the antioxidant of the present invention by adding an excess amount of ascorbic acid or ascorbic acid fatty acid ester, the antioxidant effect can be maintained more than when a saturated concentration is added.
- the addition amount of the antioxidant component of sesame is the same, and it is effective to add only an excess amount of ascorbic acid or ascorbic acid fatty acid ester.
- tocopherol may be used in addition to the antioxidant component of sesame and ascorbic acid or a fatty acid ester of ascorbic acid.
- Tocopherolone may be ⁇ , ⁇ , ⁇ , ⁇ -tocopherolone or mixed tocopherol, but ⁇ -tocopherol is preferred.
- Many highly unsaturated fatty acids such as refined fish oil or salts or esters thereof to which tocopherol is added at the stage of production are commercially available.
- tocopherol does not affect the synergistic effect of the antioxidant components of sesame and ascorbic acid or fatty acid esters of ascorbic acid. Fats and oils whose oxidative stability has been improved by adding the antioxidant component of sesame and ascorbic acid or ascorbic acid fatty acid ester are sufficiently excellent in oxidative stability by themselves, but other antioxidants are used in combination. It does not matter. Also, it can be used by mixing with fats and oils (vegetable fats and the like) having excellent oxidation stability.
- antioxidants include erythorbic acid, sodium erythorbate, isopropyl citrate, dibutylhydroxytoluene (BHT), butylhydroxyesole (BHA) and the like.
- Antioxidants that can be used in combination with foods include the tocopherols, aoi flower extract, azuki whole plant extract, aspergillus terreus extract, and ethylenediamine calcium nitrate described in Food Additives Rium, disodium ethylenediaminetetraacetate, ellagic acid, erythorbic acid, sodium erythorbic acid, orange extract, ⁇ -oryzanol, catechin, licorice extract, guayata butter, taercetin, isopropyl citrate, clove Extract, enzyme-treated isoquercitrin., Enzyme-treated rutin (extract), enzymatically decomposed lingo extract, unsaponifiable sesame oil, rice oil extract
- the composition of the present invention has excellent oxidation stability, it can be added to various foods. For example, skim milk, milk casein, milk protein, lactose, oligos, etc., sucrose and dextrin are dissolved and mixed in hot water, and then vitamins and minerals are dissolved to form an aqueous phase. And homogenize with a homogenizer. The obtained emulsion is sterilized, concentrated, and spray-dried by a conventional method to obtain a milk powder. Similarly, the composition of the present invention can be made into powdered fats and oils using various powdered bases. When adding to foods, it is determined whether to add fats and oils or powdered fats and oils depending on the nature of the food. It may be added to ordinary foods, health foods, so-called supplements, capsules and tablets.
- Refined fish oil (containing 0.5% by weight of ⁇ -tocopherol): 0 DD Oil Type 3 manufactured by Fisheries Co., Ltd. (Tuna oil is used as a raw material to purify degumming, deoxidizing, deodorizing, etc., and the peroxide value is 5 raeq. / K g or less, Acid value 1 or less, Hue Gardner Refined fish oil refined to 3 or less).
- Refined fish oil (does not contain ⁇ -tocopherol): Sampling before adding ⁇ -tocopherol during the production process of DD Oil Type 3 manufactured by Nippon Suisan Kaisha, Ltd.
- Refined fish oil (sardine oil): DD oil type 2 (Nippon Suisan Kaisha Co., Ltd.) The following is a refined fish oil refined to a hue of Gardner 3 or less: EPA 2 8% by weight, 0 ⁇ : Contains 12% by weight, ⁇ -Tocopherol 0.5% by weight).
- Sesamol Sesamol (purity 98%) manufactured by Nacalai Testa Co., Ltd.
- Ascorbic acid palmitate Ascorbic acid palmitate (purity 95% or more) manufactured by Sankyo Fuyu Co., Ltd.
- Ascorbic acid L (+)-ascorbic acid (purity 99.5%) manufactured by Nakarai Tester Co., Ltd.
- ⁇ — Tocopherol D- ⁇ -tocopherol (purity 90%) manufactured by Wako Pure Chemical Industries, Ltd.
- Eicosapentaenoic acid ethyl ester Diethyl oil was used as a raw material, and transesterified with ethanol catalyzed by metal sodium to obtain ethyl diethyl ester, which was then purified to 99% purity by precision distillation and HPLC.
- Samples were prepared by adding the following antioxidants to purified fish oil (containing 0.5% by weight of ⁇ -tocopherol).
- Example 3 The combined use of sesamol and ascorbic acid in refined fish oil has reduced the amount of oxygen absorption, and significantly improved the oxidative stability of refined fish oil compared to the case where ascorbic acid was added alone. Understand.
- Example 3 The combined use of sesamol and ascorbic acid in refined fish oil has reduced the amount of oxygen absorption, and significantly improved the oxidative stability of refined fish oil compared to the case where ascorbic acid was added alone. Understand.
- Example 4 These samples were subjected to the same storage test as in Example 2 for 11 days. The results are shown in FIG. From these results, it was found that the amount of oxygen absorbed was suppressed by increasing the amount of sesamol and ascorbic acid palmitate added to refined fish oil, and the oxidation stability of refined fish oil was improved in a dose-dependent manner. I understand.
- Example 4
- sesamol + ascorbic acid palmitate As an antioxidant to purified fish oil (does not contain ⁇ -tocopherol), sesamol (1.0 weight 0 /.) + Ascorbic acid palmitate (0.01) % By weight) was added to prepare a sample. This sample was subjected to the same storage test as in Example 1. The results are shown in FIG. It can be seen that even without tocophere, the combined use of sesamore and ascorbic acid palmitate suppressed the absorption of oxygen and greatly improved the oxidative stability of the refined fish oil.
- Samples were prepared by adding the following antioxidants to purified fish oil (0.5-tocopherol 0.5 wt./. Content) respectively.
- Roasted sesame meal 1 Add 95% ethanol to Okg 2. Add Okg and shake vigorously at 40 ° C for 2 hours After stirring, the roasted sesame cake was filtered to obtain an extract. 1.5 kg of 95% ethanol was added again to the filtered roasted sesame cake, and the mixture was vigorously stirred at 40 ° C. for 1 hour and filtered to obtain an extract. After concentrating the obtained two extracts, 240 g of ethyl acetate and 80 g of water were added, and the mixture was vigorously stirred at 45 ° C for 1 hour.
- roasted sesame cake extract 1 (containing 40 g of propylene glycol monoole, which was substantially 18 g of the roasted sesame cake extract was obtained.
- roasted sesame meal 1.0 ° 95 ° / kg. 2.0 kg of ethanol was added, and the mixture was vigorously stirred at 40 ° C for 2 hours. Then, the roasted sesame cake was filtered to obtain an extract. 1.5 kg of 95% ethanol was added again to the filtered roasted sesame cake, and the mixture was vigorously stirred at 40 ° C. for 1 hour and filtered to obtain an extract. 40 g of propylene glycol monoolate was added to the two extracts obtained, and 95% ethanol was distilled off.50 g of the roasted sesame cake extract (including 40 g of propylene glycol monoolate, which was substantially roasted) 10 g of sesame meal extract was obtained.
- Electrode 1 (reduction potential): -1 V
- Samples were prepared by adding the following antioxidants to purified fish oil (containing 0.5% by weight of ⁇ -tocopherol).
- the roasted sesame residue extract 1 (1.0 weight 0 /.) + Asukorubin palmitate (0.1 0/0)
- Example 7 roasted sesame meal extracts, like sesamol, can be used together with ascorbic acid palmitate to suppress the amount of absorbed oxygen and improve the oxidative stability of the purified fish oil.
- roasted sesame cake extract 1 (1.0 wt./.)+ascorbic acid palmitate (0.1 wt%) of Example 6 was added, and roasted sesame cake extract 2 ( (1.0% by weight) + Ascorbic acid palmitate (0.1% by weight) was added to each sample, and 10ml of each was placed in a 20ral brown bottle and stored at 60 ° C under open storage.
- the change in the concentration of alkenaals was measured using SafTest of Saftest, Inc. The results are shown in Figs.
- the addition of roasted sesame meal extract and ascorbic acid palmitate to refined fish oil produces malondialdehyde and alkenal, which are oxidized hydrolyzates of fish oil and odorants of degraded fish oil.
- Example 8 A similar effect was obtained when sesameol obtained from roasted sesame lees extract 3 using a silylation gel-open column and 0DS-HPLC in place of sesamol of Example 1 was used.
- Example 9 A similar effect was obtained when sesameol obtained from roasted sesame lees extract 3 using a silylation gel-open column and 0DS-HPLC in place of sesamol of Example 1 was used.
- Samples were prepared by adding the following antioxidants to refined fish oil (containing ⁇ -tocopherol 0.5 wt./.).
- FIGS. 10 and 11 The respective results are shown in FIGS. 10 and 11.
- ascorbic acid palmitate is first consumed (oxidized) and ascorbic acid palmitate is consumed.
- purified fish oil, ⁇ -tocopherol, and sesamol began to oxidize at the same time when the luminate was lost. Therefore, it was thought that it is important that ascorbic acid palmitate remains when ⁇ -tocoffe mouth-soles + sesamore / le + asco nolevic acid olemitate is present as an antioxidant.
- FIG. 12 shows the results obtained when 0.1% of ascorbic acid palmitate was further added on the fourth day in the same system as in FIG. In Fig.
- Samples were prepared by adding the following antioxidants to eicosapentaenoic acid ethyl ester having a purity of 9.9% (containing 0.2% of ethanol).
- antioxidant t-butylhydroxytoluene (BHT)
- the antioxidant formulation of the present invention was compared with t-butylhydroxylene (BHT), one of the commonly used antioxidants.
- BHT t-butylhydroxylene
- FIG. 1 A comparison of the antioxidant effects of BHT and the antioxidant formulation of the present invention is shown in FIG.
- the antioxidant of the antioxidant formulation according to the present invention is higher than the total amount of antioxidant contained in the antioxidant formulation (1.5%) and the sample with the overwhelming amount (10.0%) of BHT.
- the antioxidant effect of the formulation was shown to be high.
- the present invention it is possible to provide fats and oils having much higher oxidation stability than conventional fats and oils containing highly unsaturated fatty acids. This makes it possible to easily produce and store polyunsaturated fatty acids in foods, pharmaceuticals, etc. for health purposes, and to increase the type of food to be added and the amount of polyunsaturated fatty acids added. be able to.
- a highly versatile refined fish oil can be provided when refined fish oil containing EPA and DHA is used in health foods and the like.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03774122.0A EP1564278B1 (en) | 2002-11-22 | 2003-11-21 | Composition containing organic substance having double bond with improved oxidation stability |
US10/535,413 US8722104B2 (en) | 2002-11-22 | 2003-11-21 | Composition containing organic substance having double bond with improved oxidative stability |
JP2004554998A JP4424743B2 (ja) | 2002-11-22 | 2003-11-21 | 酸化安定性が向上された二重結合を有する有機物を含有する組成物 |
AU2003284617A AU2003284617A1 (en) | 2002-11-22 | 2003-11-21 | Composition containing organic substance having double bond with improved oxidation stability |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002339906 | 2002-11-22 | ||
JP2002-339906 | 2002-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004048496A1 true WO2004048496A1 (ja) | 2004-06-10 |
Family
ID=32375789
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/014905 WO2004048497A1 (ja) | 2002-11-22 | 2003-11-21 | 高度不飽和脂肪酸、その塩、またはそのエステルを含有する外用組成物 |
PCT/JP2003/014877 WO2004048496A1 (ja) | 2002-11-22 | 2003-11-21 | 酸化安定性が向上された二重結合を有する有機物を含有する組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/014905 WO2004048497A1 (ja) | 2002-11-22 | 2003-11-21 | 高度不飽和脂肪酸、その塩、またはそのエステルを含有する外用組成物 |
Country Status (11)
Country | Link |
---|---|
US (2) | US8722104B2 (ja) |
EP (2) | EP1564278B1 (ja) |
JP (2) | JPWO2004048497A1 (ja) |
KR (3) | KR20050083960A (ja) |
CN (2) | CN100352889C (ja) |
AU (2) | AU2003284617A1 (ja) |
CA (1) | CA2506611A1 (ja) |
NZ (1) | NZ540154A (ja) |
TW (2) | TW200418957A (ja) |
WO (2) | WO2004048497A1 (ja) |
ZA (1) | ZA200504059B (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007009591A1 (en) * | 2005-07-18 | 2007-01-25 | Dsm Ip Assets B.V. | Method for rejuvenating aged food oils |
WO2007132688A1 (ja) * | 2006-05-15 | 2007-11-22 | Nippon Suisan Kaisha, Ltd. | 酸化が抑制された魚粉及びその製造方法 |
JP2013001666A (ja) * | 2011-06-14 | 2013-01-07 | Yasuharu Omura | 栄養剤組成物 |
CN112574146A (zh) * | 2020-12-17 | 2021-03-30 | 自然资源部第三海洋研究所 | 丁烯酸内酯类化合物复合纳米晶体的制备方法 |
JP7473960B2 (ja) | 2020-08-05 | 2024-04-24 | 横浜油脂工業株式会社 | 高度不飽和脂肪酸含有水溶性製剤 |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
JP2006282650A (ja) * | 2005-03-31 | 2006-10-19 | Sunstar Inc | 皮膚化粧料 |
ITMI20051718A1 (it) * | 2005-09-16 | 2007-03-17 | Betafarma S P A | Composizioni igieniche e cosmetiche per il trattamento delle dermatiti atopiche |
BRPI0504797B1 (pt) * | 2005-10-27 | 2020-02-04 | Pele Nova Biotecnologia S A | formulação tópica, método de tratamento cosmético para rejuvenescimento da pele, método de tratamento cosmético e uso de uma formulação |
US7727517B2 (en) * | 2006-09-07 | 2010-06-01 | Contech Enterprises Inc. | Stabilized brood pheromone for manipulating the behavior and physiology of honey bees |
US9107396B2 (en) * | 2006-09-07 | 2015-08-18 | Oms Investments, Inc. | Stabilized synthetic brood pheromone and race-specific ratios of components for manipulating the behavior and physiology of honey bees |
US20080069942A1 (en) * | 2006-09-15 | 2008-03-20 | Glenn Roy Pizzey | Flax-stabilized fatty acid compositions and methods |
ES2316275B1 (es) * | 2007-03-16 | 2010-03-22 | Universidad Politecnica De Madrid | Proceso de sustitucion de las grasas saturadas de la leche por aceites vegetales no hidrogenados. |
WO2009070859A1 (en) * | 2007-12-04 | 2009-06-11 | Glanbia Nutritionals (Canada) Inc. | Flax-stabilized fatty acid compositions and methods |
US20110236476A1 (en) | 2008-09-02 | 2011-09-29 | Amarin Corporation Plc. | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
KR20140007973A (ko) | 2009-02-10 | 2014-01-20 | 아마린 파마, 인크. | 고중성지방혈증 치료 방법 |
AU2014203034B2 (en) * | 2009-04-29 | 2016-09-15 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
NZ627238A (en) * | 2009-04-29 | 2016-02-26 | Amarin Pharmaceuticals Ie Ltd | Stable pharmaceutical composition comprising ethyl eicosapentaenoate |
NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
MY172372A (en) | 2009-06-15 | 2019-11-21 | Amarin Pharmaceuticals Ie Ltd | Compositions and methods for lowering triglycerides |
USRE45894E1 (en) | 2009-09-22 | 2016-02-23 | Sergeant's Pet Care Products, Inc. | Spot-on pesticide composition |
CN102821606A (zh) | 2009-09-22 | 2012-12-12 | 军士宠物护理用品股份有限公司 | 定点杀虫剂组合物 |
US8614244B2 (en) | 2009-09-22 | 2013-12-24 | Segeant's Pet Care Products, Inc. | Spot-on pesticide composition |
WO2011038122A1 (en) | 2009-09-23 | 2011-03-31 | Amarin Corporation Plc | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
KR20130026428A (ko) * | 2010-03-04 | 2013-03-13 | 아마린 파마, 인크. | 심혈관 질환을 치료 및/또는 예방하기 위한 조성물 및 방법 |
EP2366766B8 (en) | 2010-03-09 | 2017-04-19 | Stepan Specialty Products, LLC | Method of treating an edible oil and oil thus obtained |
WO2011115349A1 (ko) | 2010-03-17 | 2011-09-22 | 경상대학교산학협력단 | 튜브형 구조의 생체 삽입 전지 |
AU2011300428B2 (en) | 2010-09-07 | 2016-03-24 | Dsm Nutritional Products Ag | Comestible emulsions |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
EP2762129B1 (en) * | 2011-09-29 | 2019-08-07 | The Nisshin OilliO Group, Ltd. | Cosmetic composition and cosmetic |
EP2750520B1 (en) * | 2011-09-29 | 2018-08-08 | P. Guinane Pty Ltd | Animal feed composition |
KR20200003227A (ko) * | 2011-11-01 | 2020-01-08 | 디에스엠 아이피 어셋츠 비.브이. | 산화적으로 안정한 다중불포화된 지방산 함유 오일 |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
EP2691069B1 (en) * | 2012-01-23 | 2016-09-28 | Restorsea, LLC | Cosmetic |
JP5312712B1 (ja) * | 2012-02-15 | 2013-10-09 | 株式会社明治 | 乳飲料及びその製造方法 |
CN104684389A (zh) | 2012-05-10 | 2015-06-03 | 索卢泰克斯Na有限责任公司 | 含有天然专门促消退介质及其前体的具有抗炎活性的油 |
EP2866801A4 (en) | 2012-06-29 | 2016-02-10 | Amarin Pharmaceuticals Ie Ltd | METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT SUBJECTED TO STATIN TREATMENT |
US8673325B1 (en) * | 2012-09-06 | 2014-03-18 | Dignity Sciences Limited | Cosmetic compositions comprising EPA and salicylic acid and methods of making and using same |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
CN103149311B (zh) * | 2013-01-30 | 2015-01-21 | 福建中烟工业有限责任公司 | 一种烟用香精香料中芝麻酚含量的测定方法 |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
CN104222319B (zh) * | 2013-06-21 | 2020-09-18 | 丰益(上海)生物技术研发中心有限公司 | 一种含芝麻素的油脂组合物 |
JP6238190B2 (ja) * | 2013-07-04 | 2017-11-29 | 公立大学法人大阪市立大学 | コラーゲン産生促進用、エラスチン産生促進用および/またはケラチノサイト遊走促進用組成物 |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
CN103627522A (zh) * | 2013-11-14 | 2014-03-12 | 浙江大学城市学院 | 灵芝孢子油纯天然复合抗氧化剂及提高其稳定性的方法 |
JP6089152B2 (ja) | 2013-12-13 | 2017-03-01 | レスターシー エルエルシイRestorsea, Llc | 剥脱性の毛髪保持促進製剤 |
CN104739763B (zh) * | 2013-12-31 | 2018-12-11 | 健康元药业集团股份有限公司 | 一种具有抗炎和抗血栓形成作用的静脉注射用脂肪乳剂及其制备方法和用途 |
US20160338374A1 (en) * | 2014-01-08 | 2016-11-24 | Cj Cheiljedang Corporation | Sesame oil and method for preparing same |
AU2015259509A1 (en) | 2014-05-16 | 2016-11-24 | Restorsea, Llc | Biphasic cosmetic |
KR102391827B1 (ko) | 2014-06-04 | 2022-04-27 | 디에스 바이오파마 리미티드 | Dgla를 포함하는 약제학적 조성물 및 그의 용도 |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
CN104450809B (zh) * | 2014-11-20 | 2017-09-29 | 武汉华士特工业生物技术开发有限公司 | 一种促进裂殖壶菌油脂中dha合成的方法 |
BR112017013445B1 (pt) * | 2014-12-23 | 2021-11-23 | Evonik Operations Gmbh | Processo para aumentar a estabilidade de uma composição que compreende ácidos graxos ômega 6 poli-insaturados e uso da composição de produto |
CN104593149A (zh) * | 2015-01-23 | 2015-05-06 | 河北科技师范学院 | 含有芝麻酚和芝麻酚酯的油脂抗氧剂组合 |
ES2851525T3 (es) | 2015-07-21 | 2021-09-07 | Afimmune Ltd | Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia |
US10653703B2 (en) | 2015-09-03 | 2020-05-19 | Solutex Na Llc | Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same |
BR112018016998B1 (pt) * | 2016-03-02 | 2023-10-24 | Fuji Oil Holdings Inc | Composição antioxidante de óleo e gordura e métodos para produzir a mesma |
US11957135B2 (en) | 2016-03-02 | 2024-04-16 | Fuji Oil Holdings Inc. | Chocolate-like food containing polyunsaturated fatty acid |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
KR102036138B1 (ko) * | 2016-12-06 | 2019-10-24 | 한국식품연구원 | 비가열 참깨박 추출물을 유효성분으로 포함하는 항염증 조성물 |
WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
WO2019042685A1 (en) | 2017-08-30 | 2019-03-07 | Unilever N.V. | COMPOSITION FOR PERSONAL CARE |
CN107439899A (zh) * | 2017-09-01 | 2017-12-08 | 苏州农业职业技术学院 | 一种含有芝麻素的食品用抗氧化剂组合物及具有其的食品 |
CN107541340A (zh) * | 2017-09-01 | 2018-01-05 | 苏州农业职业技术学院 | 一种食用油用天然抗氧化剂及其应用 |
CN107603734A (zh) * | 2017-09-01 | 2018-01-19 | 苏州农业职业技术学院 | 一种天然抗氧化剂增强食用油抗氧化效果的方法 |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
KR102084415B1 (ko) * | 2018-06-04 | 2020-03-04 | 코스맥스 주식회사 | 에피피노레시놀을 포함하는 화장료 조성물 |
KR102151044B1 (ko) * | 2018-07-03 | 2020-10-15 | 제이준코스메틱 주식회사 | 화장료 조성물 및 이의 제조방법 |
KR102296068B1 (ko) | 2018-09-24 | 2021-09-02 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
JP2020150822A (ja) * | 2019-03-19 | 2020-09-24 | 三菱ケミカルフーズ株式会社 | 油脂、油脂の製造方法、および油脂用酸化抑制剤 |
CN113061487A (zh) * | 2021-03-10 | 2021-07-02 | 烟台市万船口海洋生物科技有限公司 | 一种鱼油生产工艺 |
CN115414269A (zh) * | 2022-08-03 | 2022-12-02 | 陕西畅想制药有限公司 | 含芝麻酚的化妆品用超分子溶液及其制备方法与应用 |
CN115444033A (zh) * | 2022-09-22 | 2022-12-09 | 黑龙江飞鹤乳业有限公司 | 复配抗氧化剂及乳粉中氧化风味物质的测定方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01202278A (ja) | 1988-02-05 | 1989-08-15 | Nisshin Oil Mills Ltd:The | 食品用品質保持剤 |
JPH02189394A (ja) * | 1989-01-19 | 1990-07-25 | Tsukishima Shokuhin Kogyo Kk | 油脂組成物 |
JPH06298642A (ja) * | 1993-04-14 | 1994-10-25 | Japan Tobacco Inc | 高度不飽和脂肪酸含有o/w型乳剤及びその酸化防止方法 |
KR20000012871A (ko) | 1998-08-01 | 2000-03-06 | 김성년 | 위생적, 영양적으로 안전한 분쇄육 제품 |
KR20000025783A (ko) | 1998-10-14 | 2000-05-06 | 김성년 | 항산화제를 첨가하여 방사선 조사에 의한 고지방질 가공식품의산패를 억제하는 방법 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5910505A (ja) * | 1982-07-07 | 1984-01-20 | Nisshin Oil Mills Ltd:The | 油状美白化粧料 |
DE3381777D1 (de) * | 1982-12-09 | 1990-09-06 | Advanced Drug Tech | Einfach absorbierbare fettsaeureemulsionen. |
IT1223290B (it) * | 1987-07-27 | 1990-09-19 | Indena Spa | Acidi poliinsaturi ad azione vasocinetica e relative formulazioni farmaceutiche e cosmetiche |
NL9201438A (nl) * | 1992-08-11 | 1994-03-01 | Prospa Bv | Nieuwe farmaceutische samenstellingen die esters van omega-3 polyonverzadigde zuren omvatten en de toepassing ervan bij de plaatselijke behandeling van ziekelijke aandoeningen. |
GB2280449B (en) * | 1993-07-02 | 1996-10-02 | Charleville Res | A method for preparing an edible water-in-oil emulsion |
GB9321479D0 (en) * | 1993-10-18 | 1993-12-08 | Scotia Holdings Plc | Stabilisation of polyunsaturates |
DE4341000A1 (de) * | 1993-12-02 | 1995-06-08 | Beiersdorf Ag | Verwendung von L-Arginin, L-Ornithin oder L-Citrullin und topischen Zubereitungen mit diesen Stoffen |
JP3689137B2 (ja) * | 1994-08-19 | 2005-08-31 | 俊之 渡辺 | アレルギー性皮膚疾患治療用外用剤 |
JP4062639B2 (ja) * | 1996-12-23 | 2008-03-19 | 日本水産株式会社 | 皮膚外用剤 |
FR2758458B1 (fr) * | 1997-01-21 | 2000-01-07 | Jean Noel Thorel | Produits cosmetiques ou dermo-pharmaceutiques respectant l'ecologie cutanee |
US6426078B1 (en) * | 1997-03-17 | 2002-07-30 | Roche Vitamins Inc. | Oil in water microemulsion |
US20010031275A1 (en) * | 1998-02-09 | 2001-10-18 | Forse R Armour | Sesamol inhibitor of delta-5-desaturase activity and uses therefor |
JPH11269456A (ja) * | 1998-03-19 | 1999-10-05 | Suntory Ltd | 高度不飽和脂肪酸組成物 |
US6048891A (en) * | 1998-12-17 | 2000-04-11 | Loma Linda University Medical Center | Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease |
EP1420026A3 (en) * | 1999-06-23 | 2004-12-15 | Forbes Medi-Tech Inc. | Use of conjugates of phytosterol or phytostanol with ascorbic acid in treating or preventing cardiovascular disease, and compositions thereof |
US6235331B1 (en) * | 1999-07-29 | 2001-05-22 | Nisshin Flour Milling Co Ltd | Modified fish oil type material containing highly unsaturated fatty acid and/or esters thereof, and a composition containing said material |
US6384247B2 (en) * | 2000-06-19 | 2002-05-07 | Daicel Chemical Industries, Ltd. | Method of producing sesamol formic acid ester and sesamol |
ITMI20010129A1 (it) * | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
-
2003
- 2003-11-21 AU AU2003284617A patent/AU2003284617A1/en not_active Abandoned
- 2003-11-21 WO PCT/JP2003/014905 patent/WO2004048497A1/ja active Application Filing
- 2003-11-21 KR KR1020057009245A patent/KR20050083960A/ko not_active Application Discontinuation
- 2003-11-21 EP EP03774122.0A patent/EP1564278B1/en not_active Expired - Fee Related
- 2003-11-21 CA CA002506611A patent/CA2506611A1/en not_active Abandoned
- 2003-11-21 CN CNB2003801039403A patent/CN100352889C/zh not_active Expired - Fee Related
- 2003-11-21 US US10/535,413 patent/US8722104B2/en active Active
- 2003-11-21 KR KR1020057008827A patent/KR101045035B1/ko not_active IP Right Cessation
- 2003-11-21 KR KR1020117009013A patent/KR20110053281A/ko not_active Application Discontinuation
- 2003-11-21 TW TW092132691A patent/TW200418957A/zh unknown
- 2003-11-21 ZA ZA200504059A patent/ZA200504059B/en unknown
- 2003-11-21 NZ NZ540154A patent/NZ540154A/en not_active IP Right Cessation
- 2003-11-21 JP JP2004555005A patent/JPWO2004048497A1/ja active Pending
- 2003-11-21 AU AU2003284633A patent/AU2003284633B2/en not_active Ceased
- 2003-11-21 TW TW092132690A patent/TW200417595A/zh unknown
- 2003-11-21 EP EP03774145A patent/EP1571195A4/en not_active Withdrawn
- 2003-11-21 CN CNB2003801039367A patent/CN100348184C/zh not_active Expired - Fee Related
- 2003-11-21 US US10/536,013 patent/US20060289834A1/en not_active Abandoned
- 2003-11-21 JP JP2004554998A patent/JP4424743B2/ja not_active Expired - Lifetime
- 2003-11-21 WO PCT/JP2003/014877 patent/WO2004048496A1/ja active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01202278A (ja) | 1988-02-05 | 1989-08-15 | Nisshin Oil Mills Ltd:The | 食品用品質保持剤 |
JPH02189394A (ja) * | 1989-01-19 | 1990-07-25 | Tsukishima Shokuhin Kogyo Kk | 油脂組成物 |
JPH06298642A (ja) * | 1993-04-14 | 1994-10-25 | Japan Tobacco Inc | 高度不飽和脂肪酸含有o/w型乳剤及びその酸化防止方法 |
KR20000012871A (ko) | 1998-08-01 | 2000-03-06 | 김성년 | 위생적, 영양적으로 안전한 분쇄육 제품 |
KR20000025783A (ko) | 1998-10-14 | 2000-05-06 | 김성년 | 항산화제를 첨가하여 방사선 조사에 의한 고지방질 가공식품의산패를 억제하는 방법 |
Non-Patent Citations (3)
Title |
---|
NIPPON AIYO SHOKURYO GAKKAISHI, vol. 45, no. 3, 1992, pages 285 - 290 |
NIPPON AIYO SHOKURYO GAKKAISHI, vol. 45, no. 3, 1992, pages 291 - 295 |
NIPPON EIYO SHOKURYO GAKKAISHI, vol. 44, no. 6, 1991, pages 493 - 498 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007009591A1 (en) * | 2005-07-18 | 2007-01-25 | Dsm Ip Assets B.V. | Method for rejuvenating aged food oils |
KR101275406B1 (ko) | 2005-07-18 | 2013-06-14 | 디에스엠 아이피 어셋츠 비.브이. | 시효변화된 식품 오일을 재생시키기 위한 방법 |
WO2007132688A1 (ja) * | 2006-05-15 | 2007-11-22 | Nippon Suisan Kaisha, Ltd. | 酸化が抑制された魚粉及びその製造方法 |
JP2013001666A (ja) * | 2011-06-14 | 2013-01-07 | Yasuharu Omura | 栄養剤組成物 |
JP7473960B2 (ja) | 2020-08-05 | 2024-04-24 | 横浜油脂工業株式会社 | 高度不飽和脂肪酸含有水溶性製剤 |
CN112574146A (zh) * | 2020-12-17 | 2021-03-30 | 自然资源部第三海洋研究所 | 丁烯酸内酯类化合物复合纳米晶体的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1564278B1 (en) | 2018-01-10 |
KR20110053281A (ko) | 2011-05-19 |
EP1564278A1 (en) | 2005-08-17 |
ZA200504059B (en) | 2007-12-27 |
AU2003284617A1 (en) | 2004-06-18 |
WO2004048497A1 (ja) | 2004-06-10 |
JPWO2004048497A1 (ja) | 2006-03-30 |
EP1571195A1 (en) | 2005-09-07 |
TWI332978B (ja) | 2010-11-11 |
KR20050083960A (ko) | 2005-08-26 |
CN1714136A (zh) | 2005-12-28 |
EP1571195A4 (en) | 2009-08-26 |
TW200417595A (en) | 2004-09-16 |
AU2003284633A1 (en) | 2004-06-18 |
KR101045035B1 (ko) | 2011-06-30 |
KR20050072144A (ko) | 2005-07-08 |
US20060134178A1 (en) | 2006-06-22 |
US20060289834A1 (en) | 2006-12-28 |
CN100348184C (zh) | 2007-11-14 |
NZ540154A (en) | 2008-07-31 |
CA2506611A1 (en) | 2004-06-10 |
EP1564278A4 (en) | 2009-04-22 |
CN1714135A (zh) | 2005-12-28 |
JP4424743B2 (ja) | 2010-03-03 |
TW200418957A (en) | 2004-10-01 |
US8722104B2 (en) | 2014-05-13 |
CN100352889C (zh) | 2007-12-05 |
AU2003284633B2 (en) | 2008-07-10 |
JPWO2004048496A1 (ja) | 2006-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101045035B1 (ko) | 산화 안정성이 향상된 이중결합을 가진 유기물을 함유하는조성물 | |
US9301536B2 (en) | Antioxidant composition for marine oils comprising tocopherol, rosemary extract, ascorbic acid and green tea extract | |
JP5096138B2 (ja) | リグナン類化合物含有水中油滴型エマルション及びそれを含有する組成物 | |
JP3941073B2 (ja) | 油脂組成物及びそれを含む食品 | |
AU2004210244C1 (en) | Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of cholesterol and triglycerides | |
JPH07305088A (ja) | 粉末油脂組成物 | |
US20120219647A1 (en) | Antioxidant composition | |
CN113647627A (zh) | 一种粉末油脂及其制备方法 | |
US9145534B2 (en) | Fat containing composition | |
EP3213640B1 (en) | Long-chain polyunsaturated fatty-acid-containing fat and food containing same | |
JP2000325040A (ja) | 学習・記憶能力改善食品 | |
JPH0717860A (ja) | 脂溶性物質含有液剤および脂溶性物質の乳化・可溶化方法 | |
Mendoza | Enrichment of vegetable oils with phenolic antioxidants for food applications | |
JP2009225724A (ja) | アラキドン酸類含有組成物 | |
Shams et al. | A comparison between ascorbylpalmitateen capsulated with nanoliposomeas a natural antioxidant and conventional antioxidants (TBHQ And BHA) in the oxidative stability of sunflower oil | |
WO2022118887A1 (ja) | 水中油型乳化組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN JP KR NO NZ RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004554998 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003774122 Country of ref document: EP Ref document number: 1020057008827 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A39403 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057008827 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003774122 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006134178 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10535413 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10535413 Country of ref document: US |